Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) EBIT Margin (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed EBIT Margin for 12 consecutive years, with 264.41% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT Margin fell 27671.0% year-over-year to 264.41%, compared with a TTM value of 20.46% through Sep 2025, up 1516.0%, and an annual FY2024 reading of 18.1%, up 2451.0% over the prior year.
  • EBIT Margin was 264.41% for Q3 2025 at CytomX Therapeutics, down from 6.89% in the prior quarter.
  • Across five years, EBIT Margin topped out at 46.41% in Q4 2024 and bottomed at 1005.18% in Q4 2022.
  • Average EBIT Margin over 5 years is 138.42%, with a median of 24.06% recorded in 2023.
  • The sharpest move saw EBIT Margin plummeted -98144bps in 2022, then soared 100290bps in 2023.
  • Year by year, EBIT Margin stood at 23.74% in 2021, then tumbled by -4134bps to 1005.18% in 2022, then soared by 100bps to 2.28% in 2023, then surged by 2138bps to 46.41% in 2024, then tumbled by -670bps to 264.41% in 2025.
  • Business Quant data shows EBIT Margin for CTMX at 264.41% in Q3 2025, 6.89% in Q2 2025, and 44.43% in Q1 2025.